CRL Charles River Laboratoriesdata gap · 65% coveragelimited data
Health Care · Life Sciences Tools & Services · close $300.15 (2026-10-16) · latest quarter in EDGAR: 2026-06-27
Charles River Laboratories (CRL) has a ThetaGrade House Rating of 30/100 (grade F), ranking #47 of 150 in Health Care. Its strongest pillars are valuation (60) and cash flow (56); its weakest is growth (12). Data gap: 5 factors without usable data, so 65% of the method weight is covered. TTM revenue growth is -0.7% and operating margin 2.3%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift, EPS growth YoY (TTM), 4Q gross-margin change, P/E (inverted). Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 65% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→33.3%) · 12| Revenue growth YoY (TTM) (22.2%) | -0.7% | 7 |
| EPS growth YoY (TTM) (0.0%)data gap | — | — |
| Revenue acceleration (11.1%) | -3.9% | 23 |
Profitability
weight 18.5% (→20.0%) · 30| Operating margin (20.0%) | 2.3% | 30 |
| 4Q gross-margin change (0.0%)data gap | — | — |
Balance sheet
weight 18.5% (→20.0%) · 25| Net debt / EBITDA (10.7%) | 2.92× | 27 |
| Current ratio (5.3%) | 1.35 | 21 |
| Interest coverage (4.0%) | 0.84× | 23 |
Cash flow
weight 12.33% (→13.3%) · 56| FCF margin (6.7%) | 12.9% | 53 |
| FCF yield (6.7%) | 3.6% | 59 |
Valuation
weight 12.33% (→13.3%) · 60| P/E (inverted) (0.0%)data gap | — | — |
| EV/Sales (inverted) (13.3%) | 3.94× | 60 |
Technicals (EOD)
| RSI(14) | 55.6 |
| EMA 9 / 21 | 300.67 / 295.85 |
| 200-day SMA | 215.10 |
| Volume vs 20d avg | 0.65× |
| 20-day return | 6.6% |
Exit-rule monitor
- EXITRating break: House Rating below 60
- EXITFundamental miss: revenue growth negative YoY
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Operating income: OperatingIncomeLoss · Interest expense: InterestExpenseNonoperating · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close.
Get rating changes like CRL's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is CRL's House Rating?
- CRL scores 30 out of 100 (grade F) as of 2026-10-16, ranking #47 of 150 Health Care stocks we cover.
- What do analysts say about CRL?
- We do not have enough analyst-sentiment data to score this stock.
- When does CRL report earnings next?
- CRL's next earnings report is estimated for about 2026-11-04 (window 2026-11-01 to 2026-11-07), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
- Is CRL a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology